Press Archive - Arriello

Navigating the European Market for Medical Cannabis

There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.

Why aren’t more companies automating PV data capture?

Why are Safety & Pharmacovigilance departments lagging in their application of smart technology, when the pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are vast, asks John Price, a life sciences regulatory and safety consultant and advisor to Arriello.

Raising the bar in pharmacovigilance and regulatory outsourcing.

It’s all too easy to underestimate the importance of tight project management when the work being outsourced is something other than clinical trials. Yet, whether the processes involved concern international pharmacovigilance or regulatory information filing, Anna Lukyanova, COO of Arriello, warns life sciences firms not to leave outcomes to chance.

Maintaining cross-border medicines supply

Updated guidelines from the European Medicines Agency for pharmaceuticals marketing authorisation holders offer new clarity on what they must do to maintain continuity of supply of UK-registered products in Europe once the Brexit transition period ends.

Post-Brexit medicines supply continuity.

Earlier this year the European Medicines Agency updated its guidelines, clarifying how to maintain supply of UK-registered products in Europe following December 31. Here, Cecilia Avram, Senior Regulatory Affairs Manager at Arriello, assesses what needs to change.